Willis Towers Watson (WTW) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Achieved 5% organic revenue growth in Q4 and full year 2024, with adjusted operating margin expanding by 190 bps for both periods.
Completed the sale of Tranzact for $632 million, resulting in over $1 billion in pre-tax impairment charges and a full-year net loss, but expected to improve growth rates, margins, and free cash flow in 2025.
Transformation Program concluded in 2024, delivering $473 million in cumulative savings, with $27 million realized in Q4.
Launched a reinsurance joint venture with Bain Capital, marking a re-entry into the reinsurance market and expected to be a $0.25–$0.35 EPS headwind in 2025.
CEO highlighted successful completion of the Grow, Simplify and Transform strategy, with a new focus on accelerating performance and optimizing the portfolio.
Financial highlights
Q4 2024 revenue was $3,035M, up 4% year-over-year; full year revenue reached $9,930M, up 5% organically.
Q4 adjusted operating margin was 36.1% (up 190 bps); full year adjusted operating margin was 23.9% (up 190 bps).
Q4 adjusted diluted EPS was $8.13 (+9% YoY); full-year adjusted diluted EPS was $16.93 (+17% YoY).
Free cash flow for 2024 was $1.4 billion, up $184 million YoY, with a margin of 13.9%.
Q4 net income was $1.25B (up 100% YoY); full year net loss of $88M due to TRANZACT impairment.
Outlook and guidance
Targeting mid-single-digit organic growth, annual adjusted operating margin expansion, and ongoing adjusted EPS and free cash flow growth in 2025.
Expecting $1.5 billion in share repurchases in 2025, subject to market and investment opportunities.
Health segment expected to deliver high single-digit growth in 2025; Wealth to see low single-digit growth; Career to maintain mid-single-digit growth.
R&B segment to achieve ~100 bps annual margin expansion over next three years; incremental expansion at HWC and enterprise levels.
Foreign exchange expected to be a $0.18 EPS headwind in 2025; reinsurance JV to be a $0.25–$0.35 EPS headwind.
Latest events from Willis Towers Watson
- Q2 saw 6% organic growth, margin expansion, and raised 2024 guidance with strong capital returns.WTW
Q2 20248 Jul 2026 - 5% organic growth and margin gains offset TRANZACT sale, driving higher net income.WTW
Q1 20258 Jul 2026 - Organic growth and margin expansion offset divestiture impacts, boosting adjusted EPS and cash flow.WTW
Q4 20258 Jul 2026 - Q2 2025 saw 5% organic growth, margin expansion, and net income up 135% year-over-year.WTW
Q2 20258 Jul 2026 - Revenue up 8%, adjusted EPS up 19%, with margin expansion and $300M in buybacks.WTW
Q1 202630 Apr 2026 - Six major proposals, board refreshment, strong performance, and enhanced risk oversight highlighted.WTW
Proxy filing27 Mar 2026 - Key votes include director elections, auditor ratification, and share plan amendments.WTW
Proxy filing27 Mar 2026 - Q3 saw 6% revenue growth, margin gains, and a $1.67B loss from TRANZACT sale charges.WTW
Q3 202417 Jan 2026 - Sustained organic growth and margin expansion driven by innovation, efficiency, and portfolio optimization.WTW
CMD 202412 Jan 2026